Effectiveness of Supervised Exercise Program in Subacromial Impingement Syndrome

September 2, 2020 updated by: Kardelen Gencer Atalay, Marmara University

Effectiveness of Supervised Exercise Program After Subacromial- Subdeltoid Bursitis Injection in Subacromial Impingement Syndrome

Subacromial Impingement Syndrome (SIS) is a pathology resulting from mechanical repetitive compression and inflammation of the supraspinatus tendon, subacromial bursa and biceps tendon under the acromion and the coracoacromial ligament. It is the most common cause of shoulder pain, with an incidence of 44-65%. Restriction of the range of motion, along with the pain in the anterior region of the shoulder, is the main reason for disability and decreased quality of life in patients with SIS. Physical exercises to improve the range of motion, strengthening, and flexibility is the main part of treatment. The subacromial-subdeltoid bursa corticosteroid injection is shown to decrease pain during the exercise program and increase participation in the treatment. This study aims to compare the effectiveness of a supervised exercise program and home-based exercise program after subacromial-subdeltoid bursa corticosteroid injection in patients with SIS.

Study Overview

Detailed Description

Subacromial Impingement Syndrome (SIS) is a pathology resulting from mechanical repetitive compression and inflammation of the supraspinatus tendon, subacromial bursa and biceps tendon under the acromion and the coracoacromial ligament. It was first described in 1972 by Neer. Neer described SIS as a progressive syndrome with three stages, beginning with chronic bursitis and proceeding to partial and complete tears of the supraspinatus tendon, which may extend to rupture of other parts of the rotator cuff and may also involve the long biceps tendon. SIS is one of the most common causes of shoulder pain and disability reasons in both primary and secondary care. It is characterized by functional impairment of shoulder resulted from the progressive limitation of both active and passive glenohumeral movements. Restriction of the range of motion (ROM) along with the pain in the anterior region of the shoulder that gets worse with arm elevation or overhead activities is the main reason for decreased quality of life in patients with SIS. Therapeutic exercise programs are commonly used treatment methods in relieving pain and improving ROM and muscle elasticity. It was shown that such programs are more effective in reducing pain and improving functional loss than placebo in both short- and long-term. However, the optimal exercise regimen with the variety, frequency, and intensity exercises is still unclear. It is also controversial if a supervised exercise program is superior to a prescribed home-based exercise program. An efficient exercise program should target all structures affected by subacromial impingement. Therefore, both supervised and home-based exercise programs must involve rotator cuff and scapular stabilizing muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises. Corticosteroid injection into the subacromial-subdeltoid bursa is shown to increase participation, decrease pain during the exercise program, and found to be effective for symptomatic impingement. The analgesic effect provides significant improvement of functions mainly in the short-term. Therefore, some physicians prefer corticosteroid injections alone in the treatment of SIS. However, it was found that the combination of corticosteroid injection and exercise program is significantly superior to corticosteroid injections alone. Ultrasound-guided subacromial-subdeltoid bursa injections are shown to have better outcome results than blind injections for both pain and overall shoulder function. This study aims to compare the effectiveness of supervised exercise and home-based exercise programs after ultrasound-guided subacromial-subdeltoid bursa corticosteroid injection in patients with SIS.

Patients diagnosed with SIS will be included and randomized into two groups. Both groups will receive subacromial-subdeltoid bursa 1 ml (7 mg/ml) betamethasone and 4 ml of 0.5% bupivacaine injection. The injection will be performed ultrasound-guided while the patient is in a sitting position with the lateral approach. The first group will perform their exercises under the supervision of the physiotherapist in the hospital. The second group will be taken to the home-based exercise program in a brochure format. Thus, both groups will receive the same exercises every day.

The pain will be assessed with the Visual Analogue Scale (VAS), active and passive ROM will be measured with a goniometer before injection, immediately, first hour, third week, and third month after the injection. The quality of life will be evaluated by Short Form 36, and disability will be questioned by Shoulder Pain and Disability Index before injection and third week and third month after injection.

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • İstanbul, Turkey, 34899
        • Marmara University School of Medicine, Department of Physical Medicine and Rehabilitation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Symptoms lasting longer than 3 months
  2. Aged between 20-60 years
  3. The diagnosis is made by the clinician and detected by MRI

Exclusion Criteria:

  1. History of physical therapy or injection in the last 3 months
  2. Shoulder fracture history
  3. Presence of Type III (hooked) acromion
  4. Complete rupture of the rotator cuff muscles
  5. Presence of instability problem in shoulder
  6. History of shoulder surgery
  7. History of inflammatory rheumatoid disease
  8. Uncontrolled diabetes mellitus
  9. Allergy to steroids or local anesthetics (drug hypersensitivity)
  10. Known contraindications for interventional procedures (infection at the injection site, coagulopathy, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NON_RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Supervised Exercise Program
The exercise program that applied at the hospital includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Other Names:
  • Subacromial-subdeltoid bursa injection
ACTIVE_COMPARATOR: Home-based Exercise Program
The home-based exercise program given with a brochure that includes rotator cuff and scapular muscle strengthening, stretching and active-assistive range of motion exercises and proprioceptive neuromuscular facilitation exercises.
1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Other Names:
  • Subacromial-subdeltoid bursa injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain and tightness sensation
Time Frame: before treatment (T0)
Shoulder pain and sensations of tightness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable)
before treatment (T0)
Pain and tightness sensation
Time Frame: 1st hour after injection (T1)
Shoulder pain and sensations of tightness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable)
1st hour after injection (T1)
Pain and tightness sensation
Time Frame: 3rd week of treatment (T2)
Shoulder pain and sensations of tightness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable)
3rd week of treatment (T2)
Pain and tightness sensation
Time Frame: 3rd month of treatment (T3)
Shoulder pain and sensations of tightness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable)
3rd month of treatment (T3)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain and Disability - SPADI
Time Frame: before treatment (T0)
Shoulder Pain and Disability Index (SPADI) is a questionnaire developed to assess pain and disability related to shoulder problems. Pain dimension has 5 questions regarding the pain severity. Functional activities are assessed with 8 questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use. Each question is scored between 0 and 10, and high scores indicate increased severity and high scores indicate increased severity (0 = no difficulty and 10 = so difficult it require help) .The validity and reliability of the questionnaire in Turkish were conducted by Bumin et al.
before treatment (T0)
Pain and Disability - SPADI
Time Frame: 3rd week of treatment (T1)
Shoulder Pain and Disability Index (SPADI) is a questionnaire developed to assess pain and disability related to shoulder problems. Pain dimension has 5 questions regarding the pain severity. Functional activities are assessed with 8 questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use. Each question is scored between 0 and 10, and high scores indicate increased severity and high scores indicate increased severity (0 = no difficulty and 10 = so difficult it require help) .The validity and reliability of the questionnaire in Turkish were conducted by Bumin et al.
3rd week of treatment (T1)
Pain and Disability - SPADI
Time Frame: 3rd month of treatment (T2)
Shoulder Pain and Disability Index (SPADI) is a questionnaire developed to assess pain and disability related to shoulder problems. Pain dimension has 5 questions regarding the pain severity. Functional activities are assessed with 8 questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use. Each question is scored between 0 and 10, and high scores indicate increased severity and high scores indicate increased severity (0 = no difficulty and 10 = so difficult it require help) .The validity and reliability of the questionnaire in Turkish were conducted by Bumin et al.
3rd month of treatment (T2)
Quality of life- Short Form-36
Time Frame: before treatment (T0)
Short Form-36 (SF-36) is a widely-used and well-documented health-related quality of life index. The SF-36 consists of 36 questions; It survey has eight sub-dimensions, including physical functioning, role limitations due to physical problems, pain, general health perception, mental health, role limitations due to emotional problems, vitality, and social functioning, which are evaluated individually. A higher score on a 0-100 scale indicates a better quality of life.
before treatment (T0)
Quality of life- Short Form-36
Time Frame: 3rd week of treatment (T1)
Short Form-36 (SF-36) is a widely-used and well-documented health-related quality of life index. The SF-36 consists of 36 questions; It survey has eight sub-dimensions, including physical functioning, role limitations due to physical problems, pain, general health perception, mental health, role limitations due to emotional problems, vitality, and social functioning, which are evaluated individually. A higher score on a 0-100 scale indicates a better quality of life.
3rd week of treatment (T1)
Quality of life- Short Form-36
Time Frame: 3rd month of treatment (T2)
Short Form-36 (SF-36) is a widely-used and well-documented health-related quality of life index. The SF-36 consists of 36 questions; It survey has eight sub-dimensions, including physical functioning, role limitations due to physical problems, pain, general health perception, mental health, role limitations due to emotional problems, vitality, and social functioning, which are evaluated individually. A higher score on a 0-100 scale indicates a better quality of life.
3rd month of treatment (T2)
Shoulder range of motion (ROM) will be evaluated with a goniometer
Time Frame: before treatment (T0)
Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, internal and external rotation.
before treatment (T0)
Shoulder range of motion (ROM) will be evaluated with a goniometer
Time Frame: 1st hour after injection (T1)
Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, internal and external rotation.
1st hour after injection (T1)
Shoulder range of motion (ROM) will be evaluated with a goniometer
Time Frame: 3rd week of treatment (T2)
Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, internal and external rotation.
3rd week of treatment (T2)
Shoulder range of motion (ROM) will be evaluated with a goniometer
Time Frame: 3rd month of treatment (T3)
Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, internal and external rotation.
3rd month of treatment (T3)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: İlker Yağcı, Prof, Marmara University
  • Principal Investigator: Ebru Kaplan, PT, Marmara University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 5, 2019

Primary Completion (ACTUAL)

July 1, 2020

Study Completion (ACTUAL)

August 1, 2020

Study Registration Dates

First Submitted

November 25, 2019

First Submitted That Met QC Criteria

December 2, 2019

First Posted (ACTUAL)

December 5, 2019

Study Record Updates

Last Update Posted (ACTUAL)

September 3, 2020

Last Update Submitted That Met QC Criteria

September 2, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Subacromial Impingement Syndrome

Clinical Trials on Subacromial-subdeltoid bursa corticosteroid injection

3
Subscribe